Liver cancer is a malignant disease that starts in the liver, with hepatocellular carcinoma being the most common subtype. Advanced liver cancer generally refers to later-stage disease with high mortality and more limited curative treatment options.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05698459 |
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer |
RECRUITING | PHASE1 |
| NCT05603039 |
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma |
UNKNOWN | PHASE1/PHASE2 |
| NCT04906434 |
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor |
RECRUITING | PHASE1 |
| NCT04163237 |
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer |
UNKNOWN | PHASE3 |
| NCT03484962 |
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer |
WITHDRAWN | PHASE2 |
| NCT03474822 |
Plasmodium Immunotherapy for Breast and Liver Cancers |
RECRUITING | PHASE1/PHASE2 |
| NCT03146637 |
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer |
UNKNOWN | PHASE2 |
| NCT02873442 |
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer |
UNKNOWN | PHASE1/PHASE2 |
| NCT02862613 |
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer |
UNKNOWN | PHASE1/PHASE2 |
| NCT01754987 |
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective |
COMPLETED | PHASE1/PHASE2 |
